Anixa Biosciences secures Canadian patent for its ovarian cancer vaccine
Canada granted Anixa Biosciences patent 3,005,025, which covers aspects of its ovarian cancer vaccine technology. The protection complements a US patent granted in July 2025. The release, distributed by PR Newswire, does not include financial terms or clinical results for the vaccine.




